Chiyu Banking Corporation Limited

Company Information

SZ
301075
DUO RUI PHARMA

Company Profile

Industry

制造业

Company Introduction

西藏多瑞医药股份有限公司，是西藏自治区昌都市从内地招商引资的优质企业，公司经过不懈努力，整合优质资源，目前旗下拥有湖北本阳制药有限公司、湖北多瑞药业有限公司、武汉嘉诺康医药技术有限公司、湖北嘉瑞美医药技术有限公司、公安县仁康医药技术有限公司、西藏晨韵实业有限公司、西藏晟韵实业有限公司，成为集医药研发、生产、销售及医药产业投资为一体的综合性医药集团。公司以满足现代临床需求为导向，聚焦于血浆代用品、急抢救用药、儿童用药和精神类用药等特色细分领域的高端仿制药及改良型创新药，不断丰富公司的产品管线，坚持仿创结合，以化学药品制剂及其原料药的研发、生产、销售为主营业务，稳步发展，积极提升公司的研发创新能力。公司将秉承“开拓创新、追求完美”的理念，根据行业发展方向并结合自身的研发技术优势，积极响应国家号召，不断挑战原研药专利，孵化出更多麻醉科高端晶体液、肌松药、镇痛药等一系列专科药明星产品，造福民众健康，致力于成为国内优质的高科技医药企业。公司主要从事化学药品制剂及其原料药的研发、生产和销售。自成立以来，公司重点围绕围手术期和急抢救领域进行产品管线布局，目前已在血浆代用品细分领域取得了较强的竞争优势。截至本招股说明书签署之日，发行人及子公司共拥有7个药物品种、16个药品批准文号，包括醋酸钠林格注射液、复方电解质注射液和复方甘露醇注射液等。2018-2020年，公司核心产品醋酸钠林格注射液的销售收入分别为34,833.25万元、44,901.86万元和45,866.94万元，保持稳定增长态势。公司核心产品醋酸钠林格注射液，系通过自主研发而推出的国内首仿药品。临床上，醋酸钠林格注射液主要用于补充体液，调节电解质平衡、纠正酸中毒，应用场景包括麻醉科、ICU、急诊科、大外科、烧伤科等科室。截至本招股说明书签署之日，公司醋酸钠林格注射液已被河北、湖北、吉林等8个3省份列入医保药品目录。除醋酸钠林格注射液外，报告期内公司还存在少量其它产品的销售，主要包括自有产品复方电解质注射液、复方甘露醇注射液和经销产品注射用头孢噻肟钠等。

Main Business

化学药品制剂及其原料药的研发、生产和销售。

Legal Representative

邓勇

Top Executives

董事长：	邓勇
副董事长：	张绍忠
董事：	金芬,邓勤
独立董事：	王运国,刘颖斐,祁飞

Top 5 Shareholder

Shareholder name	Nature	Holding	Date
西藏嘉康时代科技发展有限公司	流通A股	58.35%	30/09/2024
青岛清畅企业管理合伙企业（有限合伙）	流通A股	7.37%	30/09/2024
嘉兴秋阳股权投资合伙企业（有限合伙）－嘉兴秋昱投资合伙企业（有限合伙）	流通A股	4.01%	30/09/2024
许波	流通A股	0.43%	30/09/2024
郭芹	流通A股	0.24%	30/09/2024

Company Secretary

敖博

Solicitors

国浩律师（上海）事务所

Auditors

天健会计师事务所（特殊普通合伙）

Tel No

027-83868180

Fax No

0895-4892099

Website

www.duoruiyy.com

aobo@duoruiyy.com;liuying@duoruiyy.com;xizangduorui@duoruiyy.com

Company Address

Register:	西藏自治区昌都市经济技术开发区A区创业大道9号
Office:	湖北省武汉市武昌区徐家棚街道秦园路38号宸胜国际中心38楼3801室

Listing Date

29/09/2021

Shares Capital

Shares Capital:	80,000,000
Total A Share:	80,000,000
Listed A Share:	80,000,000
Non-tradable A Share:	0
Other Share:	0
Total B Share:	0
Total H Share:	0

EPS(RMB)*

¥ 0.240

DPS(RMB)*

¥ 0.125

NBV Per Share(RMB)*

¥ 9.651

Market Capitalization(RMB)

1.709B

	Only Chinese content is avaliable
N / N : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only) N : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N / N : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only) N : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
*	Unadjusted Data

Disclaimer:

This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.

Information provided by: etnet
Terms and Conditions